EUROPEAN TRAINING CENTRES
Amiens - The Cathedral
Division of Nephrology-Dialysis-Transplantation- Internal Medicine-Intensive Care,
South University Hospital
Amiens, France

 

 

HEAD OF THE UNIT Albert Fournier
CLINICAL STAFF Choukroun G, Makdassi R, Presne C, Moriniere P, El Esper N, Weestel PF, Mazouz H, de Cagny B, Massy ZA, Ghazali A.  
RESEARCH AND LABORATORY Massy ZA, Choukroun G, Slama M with the collaboration of Brazier M, Kamel S, Andrejak M, Tribouilloy Ch, Maziere JC, Maziere C.  

 

CONTACT INFORMATION
E-MAIL neph@chu-amiens.fr
PHONE: +33-3-2245-5850
FAX: +33-3-2245-5651
FULL POSTAL ADDRESS Amiens-South University Hospital, Av. Rene Laennec, 80054 Amiens Cedex 1, France

 

CLINICAL FACILITIES
NEPHROLOGY BEDS N° 27
HEMODIALYSIS PATIENTS N° 190
PERITONEAL DIALYSIS PATIENTS N° 10
INTENSIVE CARE NEPHROLOGY BEDS N° 8
RENAL TRANSPLANTS /YEAR (2002) N° 50

 

RESEARCH INTERESTS

CLINICAL RESEARCH

RESEARCH PROGRAMME AND PROJECT LIST
Calcium–phosphate metabolism, vascular calcification, transplant bone disease, kidney stones, anemia and uremia cardiomyopathy, anemia and renal disease progression, angiotensin II and renal and cardiovascular protection, metabolic risk factors (inflammation, oxidative stress, homocysteine, lipids) and uremic cardiovascular disease.


BASIC RESEARCH

RESEARCH PROGRAMME AND PROJECT LIST
Vascular calcification, bone metabolism, metabolic risk factors (inflammation, oxidative stress) and uremic cardiovascular disease.

Peer Reviewed Publications in International Journals (only English) 2000-2003

1. Sadek T, Mazouz H, Bahloul H, Oprisiu R, El Esper N, El Esper I, Boitte F, Brazier M, Moriniere P, Fournier A. Sevelamer hydrochloride with or without alphacalcidol or higher dialysate calcium vs calcium carbonate in dialysis patients: an open-label, randomized study. Nephrol Dial Transplant. 2003 Mar;18(3):582-8.
2. Hottelart C, El Esper N, Rose F, Achard JM, Fournier A. Fenofibrate increases creatininemia by increasing metabolic production of creatinine. Nephron. 2002;92(3):536-41.
3. Achard J, Fournier A, Mazouz H, Caride VJ, Penar PL, Fernandez LA. Protection against ischemia: a physiological function of the renin-angiotensin system. Biochem Pharmacol. 2001 Aug 1;62(3):261-71.
4. Blanchard A, Jeunemaitre X, Coudol P, Dechaux M, Froissart M, May A, Demontis R, Fournier A, Paillard M, Houillier P. Paracellin-1 is critical for magnesium and calcium reabsorption in the human thick ascending limb of Henle. Kidney Int. 2001 Jun;59(6):2206-15.
5. Ferreira A, Ghazali A, Galvao J, Souberbielle JC, Jehle PM, Mohan S, Descamps-Latscha B, Oprisiu R, Fournier A, Drueke TB. Effect of type of dialysis membrane on bone in haemodialysis patients. Nephrol Dial Transplant. 2001 Jun;16(6):1230-8.
6. Westeel FP, Mazouz H, Ezaitouni F, Hottelart C, Ivan C, Fardellone P, Brazier M, El Esper I, Petit J, Achard JM, Pruna A, Fournier A. Cyclosporine bone remodeling effect prevents steroid osteopenia after kidney transplantation. Kidney Int. 2000 Oct;58(4):1788-96.
7. Disse-Nicodeme S, Achard JM, Desitter I, Houot AM, Fournier A, Corvol P, Jeunemaitre X. A new locus on chromosome 12p13.3 for pseudohypoaldosteronism type II, an autosomal dominant form of hypertension. Am J Hum Genet. 2000 Aug;67(2):302-10.
8. Li LF, Ouyang B, Choukroun G, Matyal R, Mascarenhas M, Jafari B, Bonventre JV, Force T, Quinn DA. Stretch-induced Il-8 depends on c-jun n-terminal and nuclear factor-{kappa}b-inducing kinases. Am J Physiol Lung Cell Mol Physiol. 2003 Apr 25
9. Jungers PY, Robino C, Choukroun G, Nguyen-Khoa T, Massy ZA, Jungers P. Incidence of anaemia, and use of epoetin therapy in pre-dialysis patients: a prospective study in 403 patients.
Nephrol Dial Transplant. 2002 Sep;17(9):1621-7.
10. Jungers P, Massy ZA, Nguyen-Khoa T, Choukroun G, Robino C, Fakhouri F, Touam M, Nguyen AT, Grunfeld JP. Longer duration of predialysis nephrological care is associated with improved long-term survival of dialysis patients. Nephrol Dial Transplant. 2001 Dec;16(12):2357-64.
11. Sheridan AM, Force T, Yoon HJ, O'Leary E, Choukroun G, Taheri MR, Bonventre JV. PLIP, a novel splice variant of Tip60, interacts with group IV cytosolic phospholipase A(2), induces apoptosis, and potentiates prostaglandin production. Mol Cell Biol. 2001 Jul;21(14):4470-81.
12. Jungers P, Choukroun G, Oualim Z, Robino C, Nguyen AT, Man NK. Beneficial influence of recombinant human erythropoietin therapy on the rate of progression of chronic renal failure in predialysis patients. Nephrol Dial Transplant. 2001 Feb;16(2):307-12.
13. Haq S, Choukroun G, Lim H, Tymitz KM, del Monte F, Gwathmey J, Grazette L, Michael A, Hajjar R, Force T, Molkentin JD. Differential activation of signal transduction pathways in human hearts with hypertrophy versus advanced heart failure.
Circulation. 2001 Feb 6;103(5):670-7.
14. Jungers P, Choukroun G, Robino C, Massy ZA, Taupin P, Labrunie M, Man NK, Landais P. Epidemiology of end-stage renal disease in the Ile-de-France area: a prospective study in 1998.
Nephrol Dial Transplant. 2000 Dec;15(12):2000-6.
15. Choukroun GJ, Marshansky V, Gustafson CE, McKee M, Hajjar RJ, Rosenzweig A, Brown D, Bonventre JV. Cytosolic phospholipase A(2) regulates golgi structure and modulates intracellular trafficking of membrane proteins. J Clin Invest. 2000 Oct;106(8):983-93.
16. Haq S, Choukroun G, Kang ZB, Ranu H, Matsui T, Rosenzweig A, Molkentin JD, Alessandrini A, Woodgett J, Hajjar R, Michael A, Force T. Glycogen synthase kinase-3beta is a negative regulator of cardiomyocyte hypertrophy. J Cell Biol. 2000 Oct 2;151(1):117-30.
17. Colas B, Collin T, Safraou F, Chatelain D, Cordonnier C, Henry X, Safar M, Andrejak M, Slama M. Direct vascular actions of methyclothiazide in remodeled mesenteric arteries from hypertensive patients. Am J Hypertens. 2001 Oct;14(10):989-94
18. Colas B, Slama M, Collin T, Safar M, Andrejak M. Mechanisms of methyclothiazide-induced inhibition of contractile responses in rat aorta. Eur J Pharmacol. 2000 Nov 10;408(1):63-7
19. Colas B, Slama M, Masson H, Colas JL, Collin T, Arnould ML, Hary L, Safar M, Andrejak M. Direct vascular actions of methyclothiazide and indapamide in aorta of spontaneously hypertensive rats. Fundam Clin Pharmacol. 2000 Jul-Aug;14(4):363-8.
20. Mentaverri R, Kamel S, Brazier M. Involvement of capacitive calcium entry and calcium store refilling in osteoclastic survival and bone resorption process. Cell Calcium. 2003 Aug;34(2):169-75.
21. Mentaverri R, Kamel S, Wattel A, Prouillet C, Sevenet N, Petit JP, Tordjmann T, Brazier M. Regulation of bone resorption and osteoclast survival by nitric oxide: possible involvement of NMDA-receptor. J Cell Biochem. 2003 Apr 15;88(6):1145-56.
22. Wattel A, Kamel S, Mentaverri R, Lorget F, Prouillet C, Petit JP, Fardelonne P, Brazier M. Potent inhibitory effect of naturally occurring flavonoids quercetin and kaempferol on in vitro osteoclastic bone resorption. Biochem Pharmacol. 2003 Jan 1;65(1):35-42.
23. Meddah B, Kamel S, Giroud C, Brazier M. Effects of ultraviolet light on free and peptide-bound pyridinoline and deoxypyridinoline cross-links. Protective effect of acid pH against photolytic degradation. J Photochem Photobiol B. 2000 Feb;54(2-3):168-74.
24. Lorget F, Kamel S, Mentaverri R, Wattel A, Naassila M, Maamer M, Brazier M. High extracellular calcium concentrations directly stimulate osteoclast apoptosis. Biochem Biophys Res Commun. 2000 Feb 24;268(3):899-903.
25. Vicca V, Massy ZA, Hennequin C, Rihane D, Drueke TB, Lacour B. Apoptotic signalling pathways involved in U937 cells exposed to low-density lipoproteins oxidized by hypochlorous acid. Free Radic Biol Med. 2003
26. Vanholder R, De Smet R, Glorieux G, Argiles A, Baurmeister U, Brunet P, Clark W, Cohen G, De Deyn PP, Deppisch R, Descamps-Latscha B, Henle T, Jorres A, Lemke HD, Massy ZA, Passlick-Deetjen J, Rodriguez M, Stegmayr B, Stenvinkel P, Tetta C, Wanner C, Zidek W; European Uremic Toxin Work Group (EUTox). Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int. 2003 May;63(5):1934-43.
27. Massy ZA, Borderie D, Nguyen-Khoa T, Drueke TB, Ekindjian OG, Lacour B. Increased plasma S-nitrosothiol levels in chronic haemodialysis patients. Nephrol Dial Transplant. 2003 Jan;18(1):153-7.
28. Drueke T, Witko-Sarsat V, Massy Z, Descamps-Latscha B, Guerin AP, Marchais SJ, Gausson V, London GM. Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease. Circulation. 2002 Oct 22;106(17):2212-7.
29. Ducloux D, Aboubakr A, Motte G, Toubin G, Fournier V, Chalopin JM, Drueke T, Massy ZA. Hyperhomocysteinaemia therapy in haemodialysis patients: folinic versus folic acid in combination with vitamin B6 and B12. Nephrol Dial Transplant. 2002 May;17(5):865-70.
30. Massy ZA, Kandoussi AM, Mamzer-Bruneel MF, Kreis H, Drueke T, Lacour B. High serum apolipoprotein AIV levels in renal transplant recipients. Clin Nephrol. 2001 Feb;55(2):156-8.
31. Nguyen-Khoa T, Massy ZA, De Bandt JP, Kebede M, Salama L, Lambrey G, Witko-Sarsat V, Drueke TB, Lacour B, Thevenin M. Oxidative stress and haemodialysis: role of inflammation and duration of dialysis treatment. Nephrol Dial Transplant. 2001 Feb;16(2):335-40.
32. Vicca S, Hennequin C, Nguyen-Khoa T, Massy ZA, Descamps-Latscha B, Drueke TB, Lacour B. Caspase-dependent apoptosis in THP-1 cells exposed to oxidized low-density lipoproteins. Biochem Biophys Res Commun. 2000 Jul 14;273(3):948-54.
33. Bostom AG, Shemin D, Bagley P, Massy ZA, Zanabli A, Christopher K, Spiegel P, Jacques PF, Dworkin L, Selhub J. Controlled comparison of L-5-methyltetrahydrofolate versus folic acid for the treatment of hyperhomocysteinemia in hemodialysis patients. Circulation. 2000 Jun 20;101(24):2829-32. Erratum in: Circulation 2000 Aug 1;102(5):598
34. Massy ZA, Kim Y, Guijarro C, Kasiske BL, Keane WF, O'Donnell MP. Low-density lipoprotein-induced expression of interleukin-6, a marker of human mesangial cell inflammation: effects of oxidation and modulation by lovastatin. Biochem Biophys Res Commun. 2000 Jan 19;267(2):536-40.

 

European Fellows programme

Specify if the Unit accepts fellows from European countries for:
Short (1-2 month) well focused training programs either clinically or laboratory oriented: Yes
Long (at least 1 year) research fellowships: Yes
Specify corresponding availability of grants: To be discussed individually (clinical training position may be available for 6 or 12 monthts when residency places are unoccupied).
Specify if the Unit may provide help for accommodation: To be discussed individually

Prerequisites for Fellowship

Language: For clinical activity French knowledge is mandatory; for clinical and basic research English is sufficient.

Work/Research experience: MD, or PhD, or Post-Doctoral position.

Other prerequisites (specify): applications should include a curriculum vitae (CV) indicating the rationale and the content of the training requested, and a support letter by the head of the home department.